MedWatch

Coloplast raises prices to offset energy cost spikes

Increasing energy uncertainty and prices are affecting the Danish medtech company, which is mitigating the consequences by raising its product prices, among other things.

Coloplast is raising some prices on products to mitigate increasing costs | Photo: Coloplast/PR

Like everybody else, Coloplast is impacted by higher prices on both raw materials and freight, but in particular, the current energy prices are becoming a headache for the Danish medtech firm’s chief financial officer, Anders Lonning-Skovgaard.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs